Sugi Predict

Sugi Predict / Compounds / SCHEMBL656252

SCHEMBL656252

SCHEMBL656252

CCOC(=O)c1cc2cccc(N)c2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.58
▸ KDM4E B2RXH2 4/20 0.58
▸ HPGD P15428 4/20 0.58
▸ RAB9A P51151 4/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ NPC1 O15118 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ LMNA P02545 2/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ GLA P06280 1/20 0.58
▸ GAA P10253 1/20 0.58
▸ ATM Q13315 1/20 0.58
▸ CDK1 P06493 1/20 0.57
▸ CCNB1 P14635 1/20 0.57
▸ HSD17B10 Q99714 3/20 0.52
▸ HRH4 Q9H3N8 1/20 0.52
▸ MMP13 P45452 5/20 0.51
▸ MMP2 P08253 4/20 0.51
▸ ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040141 0.85 KDM4E (0.61) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL31501839 0.85 KDM4E (0.61) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL4045458 0.84 RAB9A (0.59) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL10506586 0.84 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL6321559 0.84 HRH4 (0.56) ALDH1A1GLAGAAHSD17B10HRH4
SCHEMBL29865409 0.83 KDM4E (0.58) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL4040550 0.83 KDM4E (0.58) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL1301646 0.83 RAB9A (0.58) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL6307061 0.83 CDK1 (0.75) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL31501858 0.83 RAB9A (0.58) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF REGOR PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
EP-4433477-A1 PAD4 INHIBITORS AND USE THEREOF Regor Pharmaceuticals, Inc. (US) 2024-09-25 — — EP disclosed
CN-118679162-A PAD4 inhibitors and uses thereof 锐格药业公司 2024-09-20 — — CN disclosed
WO-2023083365-A1 PAD4 INHIBITORS AND USE THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-05-19 — — WO disclosed
WO-2023083365-A1 PAD4 INHIBITORS AND USE THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-05-19 — — WO disclosed
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2021-05-18 — — US disclosed
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses Rigel Pharmceuticals, Inc. (US) 2020-11-10 — — US disclosed
CN-111808079-A Indole ASK1 small molecule inhibitor and preparation method and application thereof 中国药科大学 2020-10-23 — — CN disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2020-07-14 — — US disclosed
EP-1471915-A2 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES Rigel Pharmaceuticals, Inc. (US) 2004-11-03 — — EP disclosed
US-20040038969-A1 Vanilloid receptor ligands and their use in treatments AMGEN, INC. 2004-02-26 — — US disclosed
US-20040029902-A1 Antiinflamamtory agents MIDCAP FINANCIAL TRUST 2004-02-12 — — US disclosed
WO-2003099284-A1 AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AMGEN INC. (US) 2003-12-04 — — WO disclosed
WO-2003063794-A2 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2003-08-07 — — WO disclosed
US-6140331-A FOR TREATING ANXIETY DISORDERS, DEPRESSION, PSYCHOSIS, IMPULSE CONTROL DISORDERS, ALCOHOL ABUSE, ISCHAEMIC DISEASES, CARDIOVASCULAR DISORDERS, SIDE EFFECTS INDUCED BY CONVENTIONAL ANTIPSYCHOTIC AGENTS AND SENILE DEMENTIA H. LUNDBECK A/S (DK) 2000-10-31 — — US disclosed
EP-0673375-B1 FUSED BENZO COMPOUNDS LUNDBECK & CO AS H (DK) 1999-02-24 — — EP disclosed
US-5753661-A TREATMENT OF NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS H. LUNDBECK A/S (DK) 1998-05-19 — — US disclosed
EP-0673375-A1 FUSED BENZO COMPOUNDS H. LUNDBECK A/S (DK) 1995-09-27 — — EP disclosed
WO-1994013659-A1 FUSED BENZO COMPOUNDS H. LUNDBECK A/S (DK) 1994-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF PADI4, PADI6, PADI2 ALDH1A1 273/4885KDM4E 172/4885HPGD 2711/4885
US-20040029902-A1 Antiinflamamtory agents FCER2, FCGR1A, HNMT ALDH1A1 2723/4885KDM4E 2664/4885HPGD 356/4885
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ALDH1A1 2891/4885KDM4E 2840/4885HPGD 633/4885
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ALDH1A1 2891/4885KDM4E 2840/4885HPGD 633/4885
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ALDH1A1 2891/4885KDM4E 2840/4885HPGD 633/4885
US-20040038969-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 ALDH1A1 3105/4885KDM4E 4024/4885HPGD 804/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK ALDH1A1 4184/4885KDM4E 1645/4885HPGD 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.